Article
Cytotoxic and targeted therapy for hereditary cancers
20 Jul 2016
Abstract excerpt
There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitomycin C, liposomal doxorubicin, etc. There are several molecular assays for BRCA-ness, which permit to reveal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
